Patents by Inventor Peter Andersen
Peter Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8293250Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: December 22, 2011Date of Patent: October 23, 2012Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Patent number: 8277823Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: GrantFiled: May 21, 2010Date of Patent: October 2, 2012Assignee: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 8260406Abstract: A system and a method for analysis of ECG curvature, which system involves a mathematical analysis comprising the following features where a number of different parameters are isolated and stored in a computer, where a first number of parameters are selected from at least one main group, where the selected parameters are combined in at least a first mathematical analysis. It is the object of the invention to improve mathematical analysis of ECG curvature particular for complex parts of the curvature such as notches or concavities. This can be achieved by selecting parameters from groups of symmetry, flatness, duration and/or complexity, using the parameters as input to an algorithm, where concavity intervals are evaluated on subsegments of the ECG segment and form the basis of up and downwards concavity quantification, where the system based on an algorithm detects and quantifies concavity on ECG curvatures.Type: GrantFiled: November 28, 2007Date of Patent: September 4, 2012Assignee: Aalborg UniversitetInventors: Thomas Bork Hardahl, Claus Graff, Mads Peter Andersen, Egon Toft, Johannes Jan Struijk, Joel Q. Xue
-
Patent number: 8241610Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.Type: GrantFiled: April 8, 2011Date of Patent: August 14, 2012Assignee: Statens Serum InstitutInventors: Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
-
Publication number: 20120156282Abstract: A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: Statens Serum InstitutInventors: CLAUS AAGAARD, Jes Dietrich, Peter Andersen
-
Publication number: 20120114687Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: December 22, 2011Publication date: May 10, 2012Applicant: STATENS SERUM INSTITUTInventors: Claus Aagard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20120073072Abstract: An oral care implement having a handle and a head having a flexible support from which cleaning elements extend. In one aspect, the invention can be an oral care implement comprising: a handle; a head attached to the handle; a flexible support attached to the head and having a face; a plurality of cleaning elements attached to the flexible support and projecting outwardly from the face, the cleaning elements including bristles and wall-like elements and being movable in the outward direction from the head; wherein the cleaning elements comprise a row of first cleaning elements substantially aligned along a longitudinal axis of the head and traversing a central region of the flexible support; and wherein some of the wall-like cleaning elements laterally radiate from the central region of the flexible support.Type: ApplicationFiled: December 2, 2011Publication date: March 29, 2012Applicant: Colgate-Palmolive CompanyInventors: Robert Moskovich, John J. Gatzemeyer, Bruce Russell, Peter Andersen, Luca Casini, John Hancock, Douglas Hohlbein, Eduardo Jimenez, Thomas Küchler, Tanja Langgner, Thomas Mintel, Michael Rooney, Alan Sorrentino, Joachim Storz
-
Patent number: 8142797Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: GrantFiled: May 21, 2010Date of Patent: March 27, 2012Assignee: Statens Serum InstitutInventors: Peter Andersen, Ida Rosenkrands, Anette Stryhn
-
Publication number: 20120039925Abstract: The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis, M. bovis, M. africanum). The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.Type: ApplicationFiled: April 23, 2010Publication date: February 16, 2012Applicant: STATENS SERUM INSTITUTInventors: Jes Dietrich, Peter Andersen, Carina Vingsbo Lundberg, Truc Thi Kim Than Hoang
-
Patent number: 8105614Abstract: A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves by immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes.Type: GrantFiled: June 27, 2007Date of Patent: January 31, 2012Assignee: Statens Serum InstitutInventors: Claus Aagaard, Jes Dietrich, Peter Andersen
-
Patent number: 8101193Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: May 5, 2011Date of Patent: January 24, 2012Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20120014980Abstract: Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-?, TNF-?, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 ?g, as well as 15 ?g, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 ?g increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.Type: ApplicationFiled: August 30, 2011Publication date: January 19, 2012Applicant: Statens Serum InstitutInventors: Jes Dietrich, Claud Aagaard, Peter Andersen
-
Patent number: 8091170Abstract: An oral care implement having a handle and a head having a flexible support from which cleaning elements extend. In one aspect, the invention can be an oral care implement comprising: a handle; a head attached to the handle; a flexible support attached to the head and having a face; a plurality of cleaning elements attached to the flexible support and projecting outwardly from the face, the cleaning elements including bristles and wall-like elements and being movable in the outward direction from the head; wherein the cleaning elements comprise a row of first cleaning elements substantially aligned along a longitudinal axis of the head and traversing a central region of the flexible support; and wherein some of the wall-like cleaning elements laterally radiate from the central region of the flexible support.Type: GrantFiled: May 6, 2010Date of Patent: January 10, 2012Assignee: Colgate-Palmolive CompanyInventors: Robert Moskovich, John J. Gatzemeyer, Bruce Russell, Peter Andersen, Luca Casini, John Hancock, Douglas Hohlbein, Eduardo Jimenez, Thomas Kuechler, Tanja Langgner, Joachim Storz, Thomas Mintel, Michael Rooney, Alan Sorrentino
-
Patent number: 8076469Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: GrantFiled: November 1, 2007Date of Patent: December 13, 2011Assignee: Statens Serum InstitutInventors: Peter Andersen, Karin Weldingh, Christina Veggerby Hansen, Walter Florio, Li Mei Meng Okkels, Rikke Louise Vinther Skjot, Peter Birk Rasmussen
-
Publication number: 20110287087Abstract: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.Type: ApplicationFiled: November 10, 2009Publication date: November 24, 2011Applicant: Statens Serum InstitutInventors: Dennis Christensen, Karen Smith Korsholm, Else Marie Agger, Peter Andersen
-
Publication number: 20110250224Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.Type: ApplicationFiled: April 8, 2011Publication date: October 13, 2011Applicant: Statens Serum InstitutInventors: Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
-
Publication number: 20110206713Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. Bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: May 5, 2011Publication date: August 25, 2011Applicant: STATENS SERUM INSTITUTInventors: Claus Aagard, Carina Vingsbo-Lundberg, Peter Andersen
-
Patent number: 7991458Abstract: The present invention relates to a system or method for analyzing drug influence on ECG curvature and Long QT Syndrome. The system has an input means connected to an ECG source, where different parameters of a received ECG curvature are indicated and/or isolated for indicating possible symptoms which relate to certain diseases that influence the ECG curvature. The aim of the invention is to achieve a system and a method for diagnosing Long QT Syndrome in an objective, fast and effect way by indication of a number of symptoms derivable from an ECG curve. Further aim is to achieve an effective test of drug influence on ECG curvature. The system analyzes the QT curvature of the ECG curvature for indicating Long QT Syndrome.Type: GrantFiled: October 20, 2004Date of Patent: August 2, 2011Assignee: Aalborg UniversitetInventors: Thomas Bork Hardahl, Claus Graff, Mads Peter Andersen, Egon Toft, Johannes Jan Struijk, Joergen Kim Kanters
-
Publication number: 20110184692Abstract: A system and a method for spatially ordered estimation and visualization of multi-lead electrocardiographic ST deviations induced by myocardial ischemia, in which system a plurality of ECG signals are recorded from a ECG source, which signals are stored by a processor in a memory, which processor processes the signals to obtain ST deviation, which processor performs measurement of ST deviation from each lead where the processor performs a multi-dimensional estimation of an vector representing of the spatial direction and magnitude of the underlying cardiac injury-current giving rise to the measured ST deviations, which processor hereby estimates the spatial location and severity of myocardial ischemia.Type: ApplicationFiled: October 2, 2009Publication date: July 28, 2011Applicant: AALBORG UNIVERSITETInventor: Mads Peter Andersen
-
Patent number: 7968105Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: GrantFiled: June 20, 2006Date of Patent: June 28, 2011Assignee: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen